Interestingly, in the case of MET amplification, the patients with MET amplification identified in circulating tumor DNA had a poorer PFS (2.76 months) and OS (4.08 months) compared to the patients with MET amplification identified in tumor tissue (PFS 4.85 months, OS 7.04 months). Here, MET is linked to neoplasm.